Evaluation of a fluorescent immunochromatography test for fecal calprotectin

被引:5
|
作者
Li, Runqing [1 ]
Zhao, Xiuying [1 ]
Dong, Jingxiao [1 ]
Zhu, Dong [1 ]
Wang, Tengjiao [1 ]
Yang, Song [1 ]
Zhao, Zhipeng [1 ]
Xiao, Nan [1 ]
机构
[1] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Lab Med Dept, 168 Litang Rd, Beijing 102218, Peoples R China
关键词
biomarkers; fecal calprotectin; inflammatory bowel disease; irritable bowel syndrome; INFLAMMATORY-BOWEL-DISEASE;
D O I
10.1002/jcla.23059
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Fecal calprotectin (FC) is widely used to discriminate between patients with inflammatory diseases such as inflammatory bowel disease (IBD) and functional diseases such as irritable bowel syndrome (IBS). ELISA is a time-consuming method for the measurement of FC, whereas a fluorescent immunochromatography test can obtain results in around 30 minutes and thus enables a rapid response to clinical decision. Methods Two methods, the Proglead(R) calprotectin (FC Proglead) and the BuHLMANN fCAL(R) ELISA (FC BuHLMANN), were used to quantitatively examine FC in 111 stool samples. The comparison and bias estimation of both assays were assessed using CLSI EP09c protocol. Results The two methods were highly correlated (rho = .96). Deming regression was employed to calculate the regression equation, with a slope of 1.01 and an intercept of -4.98 mu g/g. The estimated median bias (FC Proglead - FC BuHLMANN) was -4.19 mu g/g with the 95% limits of agreement (-55.59 to 47.21 mu g/g), and the estimated median percent bias was -8.71% with the 95% limits of agreement (-50.31% to 32.90%). There was 4.50% (5/111) of values outside the 95% limits of agreement. Percent biases at the FC cutoff values of 50 and 200 mu g/g between both methods evaluated by Deming regression were 8.96% and 1.49%, respectively. The biases were all less than the acceptable standard (10%). And, 99.10% of FC results were in agreement between both methods (kappa = .99, P < .001). Conclusions FC Proglead may be used as a suitable alternative to FC BuHLMANN for the disease activity assessment for patients with IBD, considering its convenience and shorter turnaround time.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin vs. Fecal Immunochemical Test: A Systematic Review and Meta-analysis
    Hu, Tingpeng
    Zhang, Zhimei
    Song, Fusheng
    Zhang, Wenguang
    Yang, Jun
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (09): : 892 - 901
  • [32] FECAL IMMUNOCHEMICAL TEST AND FECAL CALPROTECTIN SHOW DIFFERENT PROFILES IN DISEASE MONITORING FOR ULCERATIVE COLITIS
    Hiraoka, Sakiko
    Takashima, Shiho
    Inokuchi, Toshihiro
    Nakarai, Asuka
    Takahara, Masahiro
    Takei, Daisuke
    Sugihara, Yuusaku
    Harada, Keita
    Okada, Hiroyuki
    Kato, Jun
    GASTROENTEROLOGY, 2017, 152 (05) : S770 - S770
  • [33] Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease
    Inokuchi, Toshihiro
    Kato, Jun
    Hiraoka, Sakiko
    Takashima, Shiho
    Nakarai, Asuka
    Takei, Daisuke
    Sugihara, Yuusaku
    Takahara, Masahiro
    Kawano, Seiji
    Harada, Keita
    Okada, Hiroyuki
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (05) : 1078 - 1085
  • [34] Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis
    Ryu, Dae Gon
    Kim, Hyung Wook
    Park, Su Bum
    Kang, Dae Hwan
    Choi, Cheol Woong
    Kim, Su Jin
    Nam, Hyeong Seok
    MEDICINE, 2019, 98 (36)
  • [35] Fecal calprotectin and fecal immunochemical test have different associations with endoscopic activity in ulcerative colitis
    Ryu, Dae Gon
    Kim, Hyung Wook
    Park, Su Bum
    Kang, Dae Hwan
    Choi, Cheol Woong
    Kim, Su Jin
    Nam, Hyeong Seok
    Kim, Hyeong Jin
    Lee, Jae Pil
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 460 - 461
  • [36] Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease
    Inokuchi, Toshihiro
    Kato, Jun
    Hiraoka, Sakiko
    Takashima, Shiho
    Takei, Daisuke
    Nakarai, Asuka
    Sugihara, Yuusaku
    Kawano, Seiji
    Harada, Keita
    Okada, Hiroyuki
    Yamamoto, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S451 - S451
  • [37] Fecal Calprotectin in Pregnancy
    Greenup, Astrid-Jane
    Rosenfeld, Greg
    Leung, Yvette
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (10) : E49 - E50
  • [38] Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohn's Disease
    Inokuchi, Toshihiro
    Kato, Jun
    Hiraoka, Sakiko
    Takashima, Shiho
    Takei, Daisuke
    Nakarai, Asuka
    Sugihara, Yuusaku
    Takahara, Masahiro
    Harada, Keita
    Kawano, Seiji
    Okada, Hiroyuki
    GASTROENTEROLOGY, 2016, 150 (04) : S991 - S991
  • [39] RE: Contribution of Fecal Calprotectin and Fecal Immunochemical Tests to the Evaluation of Patients with Ulcerative Colitis
    Hu, Tingpeng
    Zhang, Zhimei
    Song, Fusheng
    Zhang, Wenguang
    Yang, Jun
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2024, 35 (06):
  • [40] Role of fecal calprotectin test in the work-up of IBS patients
    Delgado-Aros, S
    Cremonini, F
    GASTROENTEROLOGY, 2003, 124 (04) : 1164 - 1165